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Summary: Epilepsy outcome data should be concerned 
not only with seizure frequency, but should also assess 
present potential as a function of preexisting capabilities. 
Reported findings on outcome are not consistent, al­
though view of epilepsy outcome since the 1970’s is much 
more optimistic. The founding of an Institute of Epilep-
tology can stimulate concerted action to provide the sci­
entific community with improved information on mea­
surement and analysis of the ways in which epilepsy 
changes the lives of the patient and those immediately 
involved. Key Words: Epilepsy—Outcome assessment— 
Progno sis—Psychometrics.
Interest in the average or modal outcome of a 
disease can be motivated by very different reasons. 
Either the professional is eager to know whether the 
strategy used to treat the disease or at least its con­
sequences has been successful or the health-care 
manager is eager to know whether investments pro­
vide sufficient return economically or politically 
and, preferably, both. Most important, however, is 
the wish to inform the patient of the predicted out­
come. Anyone affected by a disease is anxious 
about future prospects, how long a cure will take, or 
whether there will be any lasting sequelae. Basi­
cally, epileptic persons and their families want to 
know the prognosis.
SEIZURE REMITTANCE
Epilepsy is often a chronic disease* Comparison 
of prevalence and incidence data suggest that epi- 
lepsy persists 12 years on the average. Prevalence 
and incidence data are not in good agreement, how­
ever, and may vary by as much as 10-fold (Table 1).
The indication of 12-year duration is derived from 
the median incidence and the median prevalence. 
However, because epilepsy that occurs in the 
course of life is a life sentence, for some, others 
must carry the burden of epilepsy for a much 
shorter time. Can we predict for our patients the 
outcome of his or her epilepsy? What exactly are 
the problems associated with epilepsy.
Address correspondence and reprint requests to Professor Dr.
H, Meinardi c/o Postbus 21, 21000 AA Heemstede, The Nether­
lands.
IMPACT ON SOCIAL FUNCTIONING
AND FAMILY
Forty years ago, I became committed to epilep- 
tology. One of my fellow students, an exceptionally 
gifted woman, had a sister who had postmalaria par­
tial epilepsy. Before onset of her seizures, this sis­
ter had performed much better academically than 
my fellow student herself, although the student later 
became a professor (however, not in epileptology, 
neurology, or psychiatry), whereas the sister with 
epilepsy could only perform menial work in a shel­
tered workshop. The impact of epilepsy on the 
whole family was clearly apparent. One day the ep­
ileptic sister had a seizure on the staircase and fell 
down the stairs. Her aging mother, who always 
walked behind her on the stairs, could no longer 
prevent the two of them from falling. The girl had to 
enter the residential section of a special center for 
epilepsy. She died a few years ago at the age of 58 
in the Instituut voor Epilepsiebestrijding, Heemst- 
ede, The Netherlands, of a sudden unexplained 
death syndrome.
Persons with epilepsy must worry not only about 
seizures, but also about the impact of epilepsy on 
their functioning and their social circumstances. 
The prime characteristic of epilepsy and the one 
easiest to gauge is the occurrence of seizures. Can 
seizures be controlled? That epilepsy lasts 12 years 
on the average has no direct bearing on this ques­
tion because persons are considered to have epi­
lepsy not only if they have had at least two seizures 
in the past year but also as long as they are receiv­
ing anti epileptic drugs (AEDs), whether or not the 
seizures are in remission. The period of 12 years
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TABLE 1. Prevalence and incidence o f epilepsy in several countries
Lowest prevalence
Prevalence
(%) Lowest incidence
Per annum per 
100,000
Japan (4) 0.15 Norway (6) 11
Italy (5) 0.15 Japan (4) 17
The Netherlands (7) 0.29
Highest prevalence Highest incidence
The Netherlands (8) 0.57
Liberia (9) 4.9 Japan (11) 145
England (10) 2.3 The Netherlands (8) 180
Indicators in review by Indicators in review by
Rutgers (12), n = 76 Rutgers (12), n = 32
publications publications
Mean 0.82 Mean 63.2
Median 0.57 Median 49.0
valerian tincture. Phenobarbital (PB) was discov­
ered just before World War I and phenytoin (PHT) 
just before World War II. In the past 25 years, two 
equally potent AEDs—carbamazepine and val­
proate— were added, along with several AEDs with 
more limited or more specific function. Recently, 
and not yet everywhere, several new AEDs have 
been registered or are about to reach the market.
Has the greater assortment in the AED armamen­
tarium made a difference in outcome? A report from 
the Instituut voor Epilepsiebestrijding, The Nether­
lands, about the total number of seizures registered 
in that hospital in the years 1910-1930, gives a fa­
vorable impression (Fig. 1). However, a source 
with a wider scope is the book Prognosis o f  Epi­
lepsy by Rodin (1), which reported on the period 
1900-1968. Rodin’s findings were not very optimis­
tic. Notwithstanding increasing knowledge about 
epilepsy and the introduction of several effective 
AEDs, the outcome of epilepsy appeared not to 
change over the years. Over that period, all cited 
studies about prognosis reported that approxi­
mately one-third of patients had their epilepsy con­
trolled by AEDs; two-thirds did not. A second point 
of reference is the book by Hauser and Hesdorffer 
(2), that quotes much better remission rates, some­
times even  80% (Table 3).
How this discrepancy between the reports before 
the 1970s and published reports in the past 25 years 
can be explained is not clear. Some researchers be­
lieve that the advent of accurate monitoring of se­
rum levels of AEDs has shown that some persons 
rapidly metabolize AEDs, and thus do not benefit 
sufficiently from them. By examining the amount of 
AED in serum, one can also ascertain whether the 
patient has regularly ingested the prescribed AED; 
this issue might otherwise not be discussed with the 
attending physician. Multiple explanations for the 
discrepancy in reports of outcome of treatment can
would be meaningful if one could discontinue pre­
scription of AEDs as soon as the seizures had been 
brought under control, but this cannot be done. The 
average rate of relapse after discontinuation of med­
ication is 30% (range 12-63%) (Table 2).
PROGNOSIS
In many respects, certainly with regard to sei- 
zure-induced risks, freedom from seizures is the 
most important outcome, and the consequences of 
chronic AED administration are of secondary im­
portance. How long must persons with epilepsy en­
dure seizures before the seizures are brought under 
control? The information available is not very 
sound. Sometimes it is difficult to determine how 
the outcome parameter was exactly defined. Usu­
ally the term remission is used, although according 
to Webster’s dictionary, remission means abate­
ment, diminution—not complete arrest. Further­
more, whether the patients reported to be in remis­
sion are seizure-free because they are appropriately 
treated with AEDs or whether they can be consid­
ered as no longer having epilepsy because they re­
main seizure-free after discontinuation of medica­
tion is often not clearly reported.
With these caveats, let us examine what has hap­
pened over the years. A century ago, the only 
"‘therapies5’ for seizure control were bromides and
TABLE 2. Relapse after discontinuation o f  AEDs
Age
group Years Relapse
Reference (yr) seizure-free (%)
~L3 4-19 >2 12
14 18-60 >3 63
2
[Average from
Table 6.4 (2)] 30
AEDs, antiepileptic drugs.
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FIG. 1. Number of seizures and spells per
100,000 days of admission in the years 1910-1930 
of patients admitted to the centres “ Meer en 
Bosch” and "Bethesda Sarepta” of the instituât 
voor Epilepsiebestrijding in The Netherlands. Af­
ter World War I, i.e., 1919/1920, phénobarbital be­
came available.
be postulated, but all are rather difficult to prove or 
disprove.
Nonetheless, if 0.6% of the population has epi­
lepsy, the latest data show that 0.12 have intracta­
ble epilepsy; e.g., the present census of England is 
58 million people. Therefore, in that country, 
—70,000 people have intractable epilepsy. In this 
instance, we are considering only uncontrollable 
seizures. Unfortunately, a problem exists which 
can be illustrated by the model of compounded 
scales (Fig. 2), as follows. To restore the balance 
disturbed by epilepsy, medication must be admin­
istered as a counter-weight. Addition of medication 
will place a greater load on the “spring/' which will
partly reduce the improvement achieved by the 
medication. It is indeed a nuisance that since the 
arm of the scale is prevented from dipping by a 
stopper, administration of too much medication as a 
counter-measure for the seizures will not be no­
ticed. That is, epilepsy is a disorder characterized 
by paroxysmal seizures, and only after a time will it 
be clear whether the increase in dosage has actually 
been effective. Titration of the exact dosage to 
maintain seizure control is therefore very difficult. 
Thus, many patients may be seizure-free while con­
suming an excessive dosage of medicine. A feature 
not disclosed by this model, which would be equiv­
alent to a shrinking of the scale, is the phenomenon
Epilepsia, Voi. 36, Suppl, 1, 1995
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TABLE 3. Percentage in terminal remission (adults)
Reference Year
Remitted
(%)
15 1907 32
16 1950 22
17 1958 32
1 1968 32
18 1984 82
(Community-based)
19 1963 32
20 1979 70
10 1983 69
of tolerance for the side effects of the AEDs, which 
unfortunately is often a pseudo tolerance; the pa­
tient is no longer aware of diminished capacities.
When the epilepsy load is so heavy that the 
amount of medication to counterbalance its effect is 
intolerable, or when an unnecessary amount of 
medication has been administered, the attention of 
the treating physician should be directed at the as­
sessment of the quality of life (QOL) provided. 
QOL outcome measures should also reveal whether 
a diminished quality exists, of which the patient is 
no longer aware, such as that induced by pseudo­
tolerance. However, the QOL of a person with ep­
ilepsy is not determined only by proper pharmaco­
therapy. Imagine what it means for a person never 
to know when the next seizure will occur. Think of 
all the precautions one must take, and the restric­
tions that are imposed, sometimes reasonably and 
sometimes unreasonably, because society is not 
able to make the fine distinctions that result from 
patients with epilepsy presenting with different con­
sequences. Furthermore, the cause of the epilepsy 
may have altered brain function, including between
FIG. 2. Epilepsy severity and epilepsy control scales. A 
model to illustrate the need to treat more severe forms of 
epilepsy with a larger amount of antiepileptic drugs (AEDs), 
which has a negative impact on outcome. It also demon­
strates the difficulty to titrate the exact amount of AEDs 
needed to control seizures.
TABLE 4. Washington Psychosocial Seizure Inventory: 
Percentage o f people with epilepsy aged >16 years with.
poor performancea
Canada: University Hospital Regional Epilepsy Unit 47
Finland: University Hospital and Epilepsy Research 31
Center
Germany: Clinic of Neuropsychiatry 10
United States: Seattle Regional Epilepsy Center, 55
study I
United States: Seattle Regional Epilepsy Center,
study II
2-10 GTCS 39
11-100 GTCS 41
>100 GTCS 58
Status epilepticus 67
United States: Mississippi—private practice and 41
EFA members
United States: Rochester, Minnesota—all residents 19
GTCS, generalized tonic-clonic seizures; EFA Epilepsy Foun­
dation of America. 
a Adapted with permission from Hauser and Hesdorffer (2).
seizures. To assess the interictal state, the Wash­
ington Psychosocial Seizure Inventory (WPSI) was 
developed by Dodrill et al. (3) to measure psycho­
social functioning in epilepsy. The scale is com­
posed of 132 items divided into the areas of family 
background, emotional adjustment, interpersonal 
adjustment, vocational adjustment, financial status, 
adjustment to seizures, medicine and medical man­
agement, and overall psychosocial functioning.
Cases that were experiencing problems were re­
ported in 10-67% of different series, depending on 
the study group characteristics (Table 4). However, 
the WPSI is not truly a desk instrument that permits 
the attending physician to gauge the psychosocial 
level of the patient. Nor does the outcome on the 
WPSI immediately clarify the reasons for the score.
This volume commemorates the founding of the 
London Institute of Epileptology. This occurs at a 
most appropriate moment. The outline of the field 
to be attacked has been charted, and tools with 
which a multidisciplinary team should be able to 
address it have been developed. At present, the 
prognosis for an individual person who has a first 
seizure is difficult to define. However, the progno­
sis that many persons with epilepsy will be very 
grateful that the London Institute of Epileptology 
»
has been established is crystal clear.
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